Marei Hadir, Malliri Angeliki
a Cell Signaling Group, Cancer Research UK Manchester Institute , The University of Manchester , Manchester , UK.
Small GTPases. 2017 Jul 3;8(3):139-163. doi: 10.1080/21541248.2016.1211398. Epub 2016 Jul 21.
Abnormal Rac1 signaling is linked to a number of debilitating human diseases, including cancer, cardiovascular diseases and neurodegenerative disorders. As such, Rac1 represents an attractive therapeutic target, yet the search for effective Rac1 inhibitors is still underway. Given the adverse effects associated with Rac1 signaling perturbation, cells have evolved several mechanisms to ensure the tight regulation of Rac1 signaling. Thus, characterizing these mechanisms can provide invaluable information regarding major cellular events that lead to aberrant Rac1 signaling. Importantly, this information can be utilized to further facilitate the development of effective pharmacological modulators that can restore normal Rac1 signaling. In this review, we focus on the pathological role of Rac1 signaling, highlighting the benefits and potential drawbacks of targeting Rac1 in a clinical setting. Additionally, we provide an overview of available compounds that target key Rac1 regulatory mechanisms and discuss future therapeutic avenues arising from our understanding of these mechanisms.
异常的Rac1信号传导与多种使人衰弱的人类疾病相关,包括癌症、心血管疾病和神经退行性疾病。因此,Rac1是一个有吸引力的治疗靶点,但寻找有效的Rac1抑制剂的工作仍在进行中。鉴于与Rac1信号传导扰动相关的不良反应,细胞已经进化出几种机制来确保对Rac1信号传导的严格调控。因此,表征这些机制可以提供有关导致异常Rac1信号传导的主要细胞事件的宝贵信息。重要的是,这些信息可用于进一步促进能够恢复正常Rac1信号传导的有效药理调节剂的开发。在这篇综述中,我们重点关注Rac1信号传导的病理作用,强调在临床环境中靶向Rac1的益处和潜在缺点。此外,我们概述了针对关键Rac1调节机制的可用化合物,并讨论了基于我们对这些机制的理解而产生的未来治疗途径。